Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score
Parallel designs with an end-of-treatment analysis are commonly used for randomised trials, but they remain challenging to conduct in rare diseases due to small sample size and heterogeneity. A more powerful alternative could be to use model-based approaches. We investigated the performance of longi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Körperschaft: | |
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 July 2025
|
| In: |
BMC medical research methodology
Year: 2025, Jahrgang: 25, Pages: 1-15 |
| ISSN: | 1471-2288 |
| DOI: | 10.1186/s12874-025-02626-x |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12874-025-02626-x Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1186/s12874-025-02626-x 
|
| Verfasserangaben: | Niels Hendrickx, France Mentré, Alzahra Hamdan, Mats O. Karlsson, Andrew C. Hooker, Andreas Traschütz, Cynthia Gagnon, Rebecca Schüle, Matthis Synofzik, Emmanuelle Comets, Xiaomei Chen, Nicole Maria Heussen, Ralf-Dieter Hilgers, Thomas Klockgether, Yevgen Ryeznik, Oleksandr Sverdlov, and EVIDENCE-RND consortium ARCA Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1946104965 | ||
| 003 | DE-627 | ||
| 005 | 20251216101744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251215s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12874-025-02626-x |2 doi | |
| 035 | |a (DE-627)1946104965 | ||
| 035 | |a (DE-599)KXP1946104965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hendrickx, Niels |e VerfasserIn |0 (DE-588)1384400419 |0 (DE-627)1946105597 |4 aut | |
| 245 | 1 | 0 | |a Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models |b a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score |c Niels Hendrickx, France Mentré, Alzahra Hamdan, Mats O. Karlsson, Andrew C. Hooker, Andreas Traschütz, Cynthia Gagnon, Rebecca Schüle, Matthis Synofzik, Emmanuelle Comets, Xiaomei Chen, Nicole Maria Heussen, Ralf-Dieter Hilgers, Thomas Klockgether, Yevgen Ryeznik, Oleksandr Sverdlov, and EVIDENCE-RND consortium ARCA Study Group |
| 264 | 1 | |c 30 July 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.12.2025 | ||
| 520 | |a Parallel designs with an end-of-treatment analysis are commonly used for randomised trials, but they remain challenging to conduct in rare diseases due to small sample size and heterogeneity. A more powerful alternative could be to use model-based approaches. We investigated the performance of longitudinal modelling to evaluate disease-modifying treatments in rare diseases using simulations. Our setting was based on a model describing the progression of the standard clinician-reported outcome SARA score in patients with ARCA (Autosomal Recessive Cerebellar Ataxia), a group of ultra-rare, genetically defined, neurodegenerative diseases. We performed a simulation study to evaluate the influence of trials settings on their ability to detect a treatment effect slowing disease progression, using a previously published non-linear mixed effect logistic model. We compared the power of parallel, crossover and delayed start designs, investigating several trial settings: trial duration (2 or 5 years); disease progression rate (slower or faster); magnitude of residual error ($$\sigma$$=2 or $$\sigma$$=0.5); number of patients (100 or 40); method of statistical analysis (longitudinal analysis with non-linear or linear models; standard statistical analysis), and we investigated their influence on the type 1 error and corrected power of randomised trials. In all settings, using non-linear mixed effect models resulted in controlled type 1 error and higher power (88% for a parallel design) than a rich (75% for a parallel design) or sparse (49% for a parallel design) linear mixed effect model or standard statistical analysis (36% for a parallel design). Parallel and delayed start designs performed better than crossover designs. With slow disease progression and high residual error, longer durations are needed for power to be greater than 80%, 5 years for slower progression and 2 years for faster progression ataxias. In our settings, using non-linear mixed effect modelling allowed all three designs to have more power than a standard end-of-treatment analysis. Our analysis also showed that delayed start designs are promising as, in this context, they are as powerful as parallel designs, but with the advantage that all patients are treated within this design. | ||
| 650 | 4 | |a Clinical trial design | |
| 650 | 4 | |a Model-based analysis | |
| 650 | 4 | |a Non-linear Mixed effect models | |
| 650 | 4 | |a Rare disease | |
| 650 | 4 | |a Simulation study | |
| 700 | 1 | |a Mentré, France |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamdan, Alzahra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Karlsson, Mats O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hooker, Andrew C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Traschütz, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gagnon, Cynthia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schüle-Freyer, Rebecca |d 1975- |e VerfasserIn |0 (DE-588)137544472 |0 (DE-627)695848283 |0 (DE-576)30411118X |4 aut | |
| 700 | 1 | |a Synofzik, Matthis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Comets, Emmanuelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chen, Xiaomei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heussen, Nicole Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hilgers, Ralf-Dieter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klockgether, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ryeznik, Yevgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sverdlov, Oleksandr |e VerfasserIn |4 aut | |
| 710 | 2 | |a ARCA Study Group, EVIDENCE-RND consortium |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC medical research methodology |d London : BioMed Central, 2001 |g 25(2025) vom: Juli, Artikel-ID 179, Seite 1-15 |h Online-Ressource |w (DE-627)326643818 |w (DE-600)2041362-2 |w (DE-576)10701467X |x 1471-2288 |7 nnas |a Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score |
| 773 | 1 | 8 | |g volume:25 |g year:2025 |g month:07 |g elocationid:179 |g pages:1-15 |g extent:15 |a Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12874-025-02626-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1186/s12874-025-02626-x |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20251215 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 137544472 |a Schüle-Freyer, Rebecca |m 137544472:Schüle-Freyer, Rebecca |d 910000 |d 911100 |e 910000PS137544472 |e 911100PS137544472 |k 0/910000/ |k 1/910000/911100/ |p 8 | ||
| 999 | |a KXP-PPN1946104965 |e 4828164790 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"326643818","origin":[{"publisher":"BioMed Central ; Springer","dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisherPlace":"London ; Berlin ; Heidelberg"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2041362-2"],"eki":["326643818"],"issn":["1471-2288"]},"title":[{"title":"BMC medical research methodology","title_sort":"BMC medical research methodology"}],"note":["Gesehen am 15.01.16"],"pubHistory":["1.2001 -"],"part":{"extent":"15","pages":"1-15","text":"25(2025) vom: Juli, Artikel-ID 179, Seite 1-15","volume":"25","year":"2025"},"language":["eng"],"disp":"Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA scoreBMC medical research methodology","type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"30 July 2025"}],"title":[{"title":"Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models","subtitle":"a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score","title_sort":"Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"corporate":[{"display":"ARCA Study Group, EVIDENCE-RND consortium","role":"aut"}],"id":{"doi":["10.1186/s12874-025-02626-x"],"eki":["1946104965"]},"physDesc":[{"extent":"15 S.","noteIll":"Illustrationen"}],"person":[{"display":"Hendrickx, Niels","given":"Niels","role":"aut","family":"Hendrickx"},{"display":"Mentré, France","given":"France","role":"aut","family":"Mentré"},{"display":"Hamdan, Alzahra","given":"Alzahra","role":"aut","family":"Hamdan"},{"display":"Karlsson, Mats O.","given":"Mats O.","role":"aut","family":"Karlsson"},{"family":"Hooker","role":"aut","given":"Andrew C.","display":"Hooker, Andrew C."},{"display":"Traschütz, Andreas","given":"Andreas","role":"aut","family":"Traschütz"},{"display":"Gagnon, Cynthia","given":"Cynthia","family":"Gagnon","role":"aut"},{"role":"aut","family":"Schüle-Freyer","display":"Schüle-Freyer, Rebecca","given":"Rebecca"},{"family":"Synofzik","role":"aut","display":"Synofzik, Matthis","given":"Matthis"},{"given":"Emmanuelle","display":"Comets, Emmanuelle","family":"Comets","role":"aut"},{"given":"Xiaomei","display":"Chen, Xiaomei","family":"Chen","role":"aut"},{"family":"Heussen","role":"aut","given":"Nicole Maria","display":"Heussen, Nicole Maria"},{"family":"Hilgers","role":"aut","display":"Hilgers, Ralf-Dieter","given":"Ralf-Dieter"},{"display":"Klockgether, Thomas","given":"Thomas","family":"Klockgether","role":"aut"},{"display":"Ryeznik, Yevgen","given":"Yevgen","family":"Ryeznik","role":"aut"},{"given":"Oleksandr","display":"Sverdlov, Oleksandr","role":"aut","family":"Sverdlov"}],"recId":"1946104965","note":["Gesehen am 15.12.2025"],"language":["eng"],"name":{"displayForm":["Niels Hendrickx, France Mentré, Alzahra Hamdan, Mats O. Karlsson, Andrew C. Hooker, Andreas Traschütz, Cynthia Gagnon, Rebecca Schüle, Matthis Synofzik, Emmanuelle Comets, Xiaomei Chen, Nicole Maria Heussen, Ralf-Dieter Hilgers, Thomas Klockgether, Yevgen Ryeznik, Oleksandr Sverdlov, and EVIDENCE-RND consortium ARCA Study Group"]}} | ||
| SRT | |a ARCASTUDYGCOMPARINGR3020 | ||